High materiality7/10
PTC Therapeutics (PTCT) PT Raised to $137 at Cantor Fitzgerald on ST-920 Acquisition
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Cantor Fitzgerald raises PTCT target to $137; current price $66.24; ST-920 acquisition cited as catalyst.
- Cantor Fitzgerald raises PTCT target to $137; current price $66.24.
Key facts
- 01
Target: $137
- 02
Posted price: $66.24
- 03
Analyst firm: Cantor Fitzgerald
- 04
Analyst: Kristen Kluska
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.